Sepetaprost is under clinical development by Santen Pharmaceutical and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Sepetaprost’s likelihood of approval (LoA) and phase transition for Ocular Hypertension took place on 11 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 11 Aug 2022 increased Sepetaprost’s LoA and PTSR for Open-Angle Glaucoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Sepetaprost Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Sepetaprost overview

Sepetaprost (DE-126) is under development for the treatment of ocular hypertension (OHT) and open-angle glaucoma (OAG). The drug candidate is administered as eye drops. It is a prostaglandin analogue. It targets prostaglandin receptors FP2 and EP3.

Santen Pharmaceutical overview

Santen Pharmaceutical (Santen) focuses on the research, development, manufacturing and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for glaucoma, bacterial conjunctivitis, dry eye, inflammation, cataract, muscae volitantes, diabetic retinopathy, retinal detachment, hyposphagma, myopia, retinal detachment, amblyopia, astigmatism, strabismus, hordeolum, VDT syndrome and others; over-the-counter products ophthalmic products; anti-allergy ophthalmic products; and medical devices such as intraocular lenses (IOLs) and other ophthalmic products. Santen operates through its group companies located in Asia, Europe and the US. It operates production facilities in Noto, and Shiga, Japan; and Suzhou, China. Santen is headquartered in Kita-ku, Osaka, Japan.

Quick View Sepetaprost LOA Data

Report Segments
  • Innovator
Drug Name
  • Sepetaprost
Administration Pathway
  • Ophthalmic
Therapeutic Areas
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.